company background image
HEST

Hester BiosciencesNSEI:HESTERBIO Stock Report

Market Cap

₹19.4b

7D

-0.5%

1Y

27.6%

Updated

27 Nov, 2021

Data

Company Financials +
HESTERBIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends3/6

HESTERBIO Stock Overview

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India.

Price History & Performance

Summary of all time highs, changes and price drops for Hester Biosciences
Historical stock prices
Current Share Price₹2,286.70
52 Week High₹3,134.00
52 Week Low₹1,601.00
Beta0.89
1 Month Change-5.99%
3 Month Change-1.15%
1 Year Change27.55%
3 Year Change84.33%
5 Year Change222.16%
Change since IPO445.17%

Recent News & Updates

Shareholder Returns

HESTERBIOIN BiotechsIN Market
7D-0.5%-0.9%-3.3%
1Y27.6%-12.1%43.0%

Return vs Industry: HESTERBIO exceeded the Indian Biotechs industry which returned -12.1% over the past year.

Return vs Market: HESTERBIO underperformed the Indian Market which returned 43% over the past year.

Price Volatility

Is HESTERBIO's price volatile compared to industry and market?
HESTERBIO volatility
HESTERBIO Average Weekly Movement3.3%
Biotechs Industry Average Movement6.9%
Market Average Movement6.0%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market3.8%

Stable Share Price: HESTERBIO is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: HESTERBIO's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987428Rajiv Gandhihttps://www.hester.in

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India. It operates through Poultry healthcare, Animal Healthcare, and Others segments. The company provides poultry vaccines for diseases, such as newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reo, marek’s disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, etc. It also offers vaccines for large animals against Goat Pox, Peste des Petits Ruminants, and Brucellosis diseases, as well as infections, reproductive disorders, theileriosis, and parasitic diseases.

Hester Biosciences Fundamentals Summary

How do Hester Biosciences's earnings and revenue compare to its market cap?
HESTERBIO fundamental statistics
Market Cap₹19.40b
Earnings (TTM)₹451.46m
Revenue (TTM)₹2.50b

43.0x

P/E Ratio

7.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HESTERBIO income statement (TTM)
Revenue₹2.50b
Cost of Revenue₹664.42m
Gross Profit₹1.84b
Expenses₹1.39b
Earnings₹451.46m

Dividends

0.4%

Current Dividend Yield

19%

Payout Ratio

Valuation

Is Hester Biosciences undervalued compared to its fair value and its price relative to the market?

42.98x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: HESTERBIO (₹2286.7) is trading above our estimate of fair value (₹234.97)

Significantly Below Fair Value: HESTERBIO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HESTERBIO is poor value based on its PE Ratio (43x) compared to the Asian Biotechs industry average (38.2x).

PE vs Market: HESTERBIO is poor value based on its PE Ratio (43x) compared to the Indian market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: HESTERBIO is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: HESTERBIO is overvalued based on its PB Ratio (8x) compared to the IN Biotechs industry average (4.3x).


Future Growth

How is Hester Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HESTERBIO's forecast earnings growth (19.6% per year) is above the savings rate (6.7%).

Earnings vs Market: HESTERBIO's earnings (19.6% per year) are forecast to grow slower than the Indian market (20.3% per year).

High Growth Earnings: HESTERBIO's earnings are forecast to grow, but not significantly.

Revenue vs Market: HESTERBIO's revenue (19.4% per year) is forecast to grow faster than the Indian market (12.7% per year).

High Growth Revenue: HESTERBIO's revenue (19.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HESTERBIO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Hester Biosciences performed over the past 5 years?

6.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HESTERBIO has high quality earnings.

Growing Profit Margin: HESTERBIO's current net profit margins (18.1%) are higher than last year (13.9%).


Past Earnings Growth Analysis

Earnings Trend: HESTERBIO's earnings have grown by 6.7% per year over the past 5 years.

Accelerating Growth: HESTERBIO's earnings growth over the past year (69.4%) exceeds its 5-year average (6.7% per year).

Earnings vs Industry: HESTERBIO earnings growth over the past year (69.4%) exceeded the Biotechs industry 51.1%.


Return on Equity

High ROE: HESTERBIO's Return on Equity (18.1%) is considered low.


Financial Health

How is Hester Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: HESTERBIO's short term assets (₹1.7B) exceed its short term liabilities (₹650.0M).

Long Term Liabilities: HESTERBIO's short term assets (₹1.7B) exceed its long term liabilities (₹1.2B).


Debt to Equity History and Analysis

Debt Level: HESTERBIO's net debt to equity ratio (38.1%) is considered satisfactory.

Reducing Debt: HESTERBIO's debt to equity ratio has reduced from 53% to 42.8% over the past 5 years.

Debt Coverage: HESTERBIO's debt is well covered by operating cash flow (33.3%).

Interest Coverage: HESTERBIO's interest payments on its debt are well covered by EBIT (25.3x coverage).


Balance Sheet


Dividend

What is Hester Biosciences's current dividend yield, its reliability and sustainability?

0.44%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: HESTERBIO's dividend (0.44%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: HESTERBIO's dividend (0.44%) is low compared to the top 25% of dividend payers in the Indian market (1.47%).


Stability and Growth of Payments

Stable Dividend: HESTERBIO's dividend payments have been volatile in the past 10 years.

Growing Dividend: HESTERBIO's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (18.7%), HESTERBIO's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Rajiv Gandhi (59 yo)

16.67yrs

Tenure

₹51,530,000

Compensation

Mr. Rajiv Dinesh Gandhi has been the Executive Chief Executive Officer and Managing Director of Hester Biosciences Limited (Former Hester Pharmaceuticals Limited) since March 2005. In 1995, Mr. Gandhi set...


CEO Compensation Analysis

Compensation vs Market: Rajiv's total compensation ($USD686.59K) is above average for companies of similar size in the Indian market ($USD197.59K).

Compensation vs Earnings: Rajiv's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: HESTERBIO's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: HESTERBIO's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hester Biosciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Hester Biosciences Limited
  • Ticker: HESTERBIO
  • Exchange: NSEI
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹19.402b
  • Shares outstanding: 8.51m
  • Website: https://www.hester.in

Number of Employees


Location

  • Hester Biosciences Limited
  • Pushpak
  • 1st Floor
  • Ahmedabad
  • Gujarat
  • 380006
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/27 12:06
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.